Abstract: Provided is a method of selecting a stent for implantation in the circulatory system of a human being. The method comprises obtaining a blood sample from a patient who requires implantation of a stent and testing said blood sample to determine a platelet coagulability level. The determined platelet coagulability level of said blood sample is compared with a threshold level of blood platelet coagulability. A determined platelet coagulability level above said threshold level indicates that a risk of restenosis is relatively high. If the determined platelet coagulability level is below said threshold level, a bare metal stent is selected. If the determined platelet coagulability level is at or above said threshold level, a drug-eluting stent is selected.
Abstract: The invention relates to a hemostatic composition comprising a mixture of cellulose-based short and long fibers, preparation and use thereof.
Type:
Grant
Filed:
November 8, 2016
Date of Patent:
November 27, 2018
Assignees:
Omrix Biopharmaceuticals Ltd., Ethicon, Inc.
Inventors:
Erez Ilan, Omri Faingold, Nataly Freizus, Ronen Eavri, Dwayne Looney, Sridevi Dhanaraj, James Galloway, Walter Danker
Abstract: The present invention relates to a method of obtaining antifungal, anticandidal and antibacterial textile products. The objective of the present invention is to obtain an antimicrobial product, which enables to reduce the infectious diseases that are transmitted or spread by textile products, reduces extra cost and energy spent for ensuring hygiene, and increases hygienity of disposable textile products. A solution of triclosan, chlorhexidine and disodium octaborate pentahydrate is used in the method of the present invention. The said solution enables the hydrophobic textile products to be transformed into hydrophilic products and thereby enables the antimicrobial agents in the solution to be coded into the textile products.
Abstract: The invention provides a sterile lyophilizate composition having improved stability and shelf-life, the lyophilizate having from 30 to 100% of Mesna and 0 to 70% of an excipient. The invention further provides a process for the preparation of the sterile lyophilizate composition and a dosage unit formulation with the lyophilizate composition.
Abstract: A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1bright cells and/or progeny thereof and/or soluble factors derived therefrom.
Abstract: The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
Abstract: A tendon repair implant for treatment of a partial thickness tear in the supraspinatus tendon of the shoulder is provided. The implant may incorporate features of rapid deployment and fixation by arthroscopic surgery that compliment current procedures; tensile properties that result in desired sharing of anatomical load between the implant and native tendon during rehabilitation; selected porosity and longitudinal pathways for tissue in-growth; sufficient cyclic straining of the implant in the longitudinal direction to promote remodeling of new tissue to tendon-like tissue; and, may include a bioresorbable construction to provide transfer of additional load to new tendon-like tissue and native tendon over time.
Type:
Grant
Filed:
June 16, 2016
Date of Patent:
October 23, 2018
Assignee:
ROTATION MEDICAL, INC.
Inventors:
Craig Van Kampen, Nathaniel Zenz-Olson, Thomas A. Westling, Charles L. Euteneuer
Abstract: Devices and methods are described for the treatment of heart conditions such as heart failure with preserved ejection fraction, including diastolic heart failure, by performing a pericardial modification procedure. Intraoperative test procedures for assessing the efficacy of the pericardial modification procedure are also described.
Type:
Grant
Filed:
November 18, 2016
Date of Patent:
October 16, 2018
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Samuel J. Asirvatham, Barry A. Borlaug, Christopher V. DeSimone, Prakriti Gaba
Abstract: In various embodiments a payload molecule or drug molecule delivery system is disclosed. The system comprises a plurality of functionalized discrete carbon nanotubes having specific properties. The composition can comprise a plurality of discrete carbon nanotubes that have at least a portion of the carbon nanotubes with a number average (ratio of number average contour length to end to end length) of greater than 1.1 and up to about 3. These discrete carbon nanotubes having the specified ratio of number average (tube contour length (TCL) to number average tube end-end length (TEE)) ratio are not only discrete (separated) from one another, but are also controlled in their alignment such that processability and mechanical strength properties are both enhanced. Utility of the molecular rebar composition includes, but is not limited to improved payload molecule delivery, such as drug delivery, into body of an animal, such as human.
Type:
Grant
Filed:
February 21, 2015
Date of Patent:
October 2, 2018
Assignee:
Molecular Rebar Design, LLC
Inventors:
Clive P. Bosnyak, Kurt W. Swogger, Nancy Henderson, Paul Everill
Abstract: Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY™ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.
Abstract: Systems and methods of localizing or delivery cells, biologics and/or drugs to a specific target area to treat pelvic health disorders are provided. A treatment composition including cells, biologics and/or drugs are associated with magnetic particulates, and the positioning of these materials is facilitated through use of a magnetic field-generating device that is configured to be placed on or into a pelvic anatomical structure. Certain embodiments directed to the treatment of ED in male patients can include a cell based therapy system.
Type:
Grant
Filed:
June 5, 2017
Date of Patent:
September 18, 2018
Assignee:
Boston Scientific Scimed, Inc.
Inventors:
Natalie Ann Borgos, Tania M. Schroeder, David J. Yonce, Robert E. Lund, Suranajan Roychowdhury
Abstract: Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.
Abstract: Drug delivery devices, medicaments, and methods are provided for the intraperitoneal treatment of ovarian cancer. An implantable device for drug delivery includes an elongated, flexible device having a housing defining a reservoir that contains a drug in solid or semi-solid form, and configured to be wholly deployed within the peritoneal cavity of a patient and continuously release a therapeutically effective amount of the drug over a period of at least 24 hours. A medicament includes cisplatin for administration into the peritoneal cavity of a patient continuously over a treatment period of at least 24 hours. A method of drug delivery includes implanting within the peritoneal cavity of a patient an elongated, flexible device having a reservoir containing a drug, solubilizing the drug at least in part with peritoneal fluid, and releasing an effective amount of the solubilized drug from the reservoir continuously for a period of at least 24 hours.
Type:
Grant
Filed:
May 9, 2013
Date of Patent:
August 28, 2018
Assignees:
Massachusetts Institute of Technology, The General Hospital Corporation
Inventors:
Michael J. Cima, Hongye Ye, Marcela Del Carmen, Michael Birrer
Abstract: Disclosed is a medical device having a first implant portion having a proximal end, a second implant portion connected to the first implant portion, the second implant portion having a distal end, and a driver assembly removably connected to the distal end, the driver assembly comprising a drill connected to the distal end at a connection.
Type:
Grant
Filed:
July 19, 2016
Date of Patent:
August 28, 2018
Assignee:
Tyber Medical, LLC
Inventors:
Jeffrey Tyber, Rui Ferreira, Christopher Faresich, Donald Buss
Abstract: A Domain Name Service (DNS) administration computer system for centralized DNS administration includes at least one processor. The processor is configured to identify a first administrative action to be performed on a first DNS server. The processor is also configured to generate a first operation request message in an administrative language. The processor is further configured to transmit the first operation request message to a first DNS interface module associated with a first DNS server type of the first DNS server. The first DNS interface module is configured to perform one or more operational interactions with the first DNS server based at least in part on the first operation request, thereby performing the first administrative action on the first DNS server.
Abstract: In an example, a process includes chemically reacting a polyhydroxyalkanoate (PHA) material having a carboxylic-acid terminated side-chain with an azide material to form a polyisocyanate material.
Type:
Grant
Filed:
March 28, 2016
Date of Patent:
August 7, 2018
Assignee:
International Business Machines Corporation
Inventors:
Scott B. King, Brandon M. Kobilka, Joseph Kuczynski, Jason T. Wertz
Abstract: The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.
Type:
Grant
Filed:
March 14, 2016
Date of Patent:
July 31, 2018
Assignee:
AQUESTIVE THERAPEUTICS, INC.
Inventors:
Garry L. Myers, Samuel D. Hilbert, Bill J. Boone, B. Arlie Bogue, Pradeep Sanghvi, Madhusudan Hariharan
Abstract: Bone grafts and constructs including stem cells are provided. Example bone grafts include osteogenic stem cells seeded on a scaffold of osteoconductive cortico-cancellous chips and/or osteoinductive demineralized bone. Example constructs include extracellular matrix on a synthetic scaffold, in which the ECM is secreted from MSCs seeded onto the synthetic scaffold. Also provided are methods of making the present bone grafts and scaffolds. Further provided are methods of promoting bone healing and treating wound healing, by administering the present bone grafts and constructs to a mammal in need thereof. Also provided are kits that include the present bone grafts and/or constructs, or components thereof.
Type:
Grant
Filed:
November 29, 2016
Date of Patent:
July 17, 2018
Assignee:
Globus Medical, Inc.
Inventors:
Archana Bhat, Shairali Rao, Daniel Laskowitz
Abstract: There is described inter alia a medical device having a surface which comprises a coating layer, said coating layer being a biocompatible composition comprising an anti-coagulant entity capable of interacting with mammalian blood to prevent coagulation or thrombus formation, which anti-coagulant entity is covalently attached to said surface through a linker comprising a thioether.
Abstract: The present invention generally relates to articles of manufacture, such as medical devices, having a non-fouling surface comprising a grafted polymer material. The surface resists the adhesion of biological material.
Type:
Grant
Filed:
November 5, 2014
Date of Patent:
July 10, 2018
Assignee:
ARROW INTERNATIONAL, INC.
Inventors:
Zheng Zhang, Jun Li, Chad C. Huval, Michael A. Bouchard, Arthur J. Coury, Christopher R. Loose
Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite, or a prodrug thereof.
Type:
Grant
Filed:
February 13, 2008
Date of Patent:
July 3, 2018
Assignee:
Indivior UK Limited
Inventors:
Eric Dadey, Qi Li, Christopher Lindemann
Abstract: A composite implant comprising an injectable matrix material which is flowable and settable, and at least one reinforcing element for integration with the injectable matrix material, the at least one reinforcing element adding sufficient strength to the injectable matrix material such that when the composite implant is disposed in a cavity in a bone, the composite implant supports the bone. A method for treating a bone comprising: selecting at least one reinforcing element to be combined with an injectable matrix material to form a composite implant capable of supporting the bone; positioning the at least one reinforcing element in a cavity in the bone; flowing the injectable matrix material into the cavity wherein the injectable matrix material interfaces with the at least one reinforcing element; and transforming the injectable matrix material from a flowable state to a nonflowable state to establish a static structure that supports the adjacent bone.
Type:
Grant
Filed:
May 23, 2014
Date of Patent:
July 3, 2018
Assignee:
206 ORTHO, Inc.
Inventors:
Jeffrey A. D'Agostino, Robert S. Whitehouse, Andrew J. Carter, Arthur Watterson, Joseph P. Lane, Ian D. McRury, Samantha Marchetti, Nikole Seil
Abstract: A method (and the resulting product) of making a medical implant device for releasing self-contained drugs on a controlled basis wherein the method utilizes, at least in part, computer-controlled 3-D printing equipment to deposit via nozzles portions of one or more layers of the medical implant product. The implant has an outer impervious coating, an inner matrix core, an opening and an optional bonding layer.
Abstract: An intravaginal device that provides biologically active circulating concentrations of an aromatase inhibitor for at least about of 4 days. Liposome-based and a wax-based formulations were used to assess letrozole diffusion through bovine vaginal mucosa in a diffusion chamber study. The wax-based vehicle was selected for further development of a letrozole intravaginal device based on its steady release rate. The addition of a letrozole-containing gel coating improved initial absorption and hastened the increase on plasma concentrations of the active ingredient, while the letrozole-containing wax-based vehicle maintained prolonged delivery from the intravaginal device.
Type:
Grant
Filed:
April 17, 2014
Date of Patent:
June 26, 2018
Assignee:
University of Saskatchewan
Inventors:
Gregg Patrick Adams, Maria Jimena Yapura, Roger A. Pierson, Ildiko Badea
Abstract: The invention is a retinal implant device to stimulate a retina of an eye thereby producing a specific effect in the eye, such as a vision or drug treatment of a chronic condition. The retinal device is made of a retinal implant that is positioned subretinally and that contains a multitude of stimulation sites that are in contact with the retina. A connection carries a stimulating electrical signal or a drug. The connection passes transretinally through the retina and into a vitreous cavity of the eye, thereby minimizing damage to a nutrient-rich choroid. A lead is attached to a source of drugs or electrical energy, which is located outside the eye. The lead passes through a sclera at a point near a front of the eye to avoid damage to the retina.
Abstract: Systems and methods for treating ocular disorders are disclosed. One system has a delivery instrument, with a non-linear axis, configured to be inserted into an anterior chamber of an eye and moved to a location proximate a physiologic outflow pathway of the eye. The delivery instrument carries an implant that has a distal end sized for insertion into tissue such that aqueous humor drains from the anterior chamber to the physiologic outflow pathway. One method involves inserting a non-linear portion of a delivery device into the anterior chamber to position an implant within the eye. Another method involves using a delivery device with a curved distal portion to implant an implant at a location communicating with the physiologic outflow pathway. The delivery can be through a corneal incision and the implant can comprise a drug.
Type:
Grant
Filed:
December 27, 2010
Date of Patent:
June 5, 2018
Assignee:
GLAUKOS CORPORATION
Inventors:
Hosheng Tu, Gregory T. Smedley, David Steven Haffner, Barbara A. Niksch, Richard A. Hill, Olav B. Bergheim
Abstract: A staple cartridge that comprises a cartridge body, wherein a plurality of staple cavities are defined in the cartridge body is disclosed. The staple cartridge further comprises a plurality of staples removably positioned in the staple cavities and a compressible layer releasably positioned adjacent to the cartridge body. The compressible layer comprises a plurality of compression springs.
Type:
Grant
Filed:
November 13, 2014
Date of Patent:
May 22, 2018
Assignee:
Ethicon LLC
Inventors:
Chester O. Baxter, III, Frederick E. Shelton, IV, Jeffrey S. Swayze, Taylor W. Aronhalt, Katherine J. Schmid
Abstract: Disclosed herein are tissue scaffold materials with microspheres of one density embedded in hydrogel of a different density. The disclosed materials have improved ability to facilitate cellular invasion and vascularization for wound healing and tissue regeneration. The inventors have found that materials having components with different densities promotes invasion of cells, including desirable cells such as fibroblasts and endothelial precursor cells, into the scaffold.
Type:
Grant
Filed:
November 19, 2014
Date of Patent:
May 15, 2018
Assignee:
CORNELL UNIVERSITY
Inventors:
Jason Spector, Abraham D. Stroock, John Morgan
Abstract: Provided herein is a biodegradable elastomeric patch that can be implanted on a heart or other portions of the cardiovascular system to repair tissue deficiencies or tissue damage. The biodegradable elastomeric patch may be engineered to have mechanical properties similar to that of soft tissue and to provide mechanical support to the damaged tissue. The biodegradable elastomeric patch also may comprise therapeutic agents to aid in the healing process. Methods also are provided for using a biodegradable elastomeric patch for treating patients suffering from tissue damage or tissue deficiencies in the cardiac or cardiovascular system.
Type:
Grant
Filed:
January 15, 2015
Date of Patent:
May 15, 2018
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Kazuro Lee Fujimoto, Jianjun Guan, Bradley B. Keller, Kimimasa Tobita, William R. Wagner
Abstract: The present technology provides new compositions comprising at least one cross-linked co-polymer. In some embodiments, the polyacrylamide co-polymer comprises water soluble subunits, cross-linking subunits, and iron chelating subunits. In other embodiments, the co-polymer comprises water soluble units, cross-linking subunits, and substituted subunits, which can be conjugated with iron-chelating agents. When these new particles are exposed to certain environments, such the presence of strong acids or oxidation agents, these particles are capable of breaking up so that the iron chelating agents can chelate iron or other metals from their environments. Methods to prepare these new compositions are also provided. These compositions or compositions comprising nanogels of the present technology may be used to treat metal overload conditions such as iron overload resulting from chronic transfusions.
Abstract: The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body, wherein the reservoir contains a therapeutic or diagnostic agent, and an agent-permeable seal disposed over the at least one opening. The invention further provides a method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering a sustained release drug delivery particle of the invention. The invention also provides methods of fabricating a drug-eluting particle for releasing therapeutic agents.
Type:
Grant
Filed:
November 7, 2016
Date of Patent:
May 8, 2018
Assignee:
pSivida US, Inc.
Inventors:
Paul Ashton, Hong Guo, Jianbing Chen, Leigh T. Canham
Abstract: A method of treating an injury to hyaline cartilage in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of amelogenin.
Type:
Grant
Filed:
August 28, 2014
Date of Patent:
May 1, 2018
Assignees:
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Inventors:
Dan Deutsch, Amir Haze, Anat Blumenfeld
Abstract: Various methods can be employed to apply an antimicrobial coating to the outer surface of catheter tubing. The antimicrobial coating minimizes the risk of microbe colonization on the outer surface of the catheter tubing when the catheter tubing is positioned within the vasculature of a patient. A catheter can be manufactured using a pre-treatment process which applies the antimicrobial coating to the catheter tubing prior to applying a lubricant over top of the coating. The lubricant can function to retain the coating on the outer surface and also to limit the diffusion of the antimicrobial agent from the coating. A catheter can include an antimicrobial coating that does not block the visibility of flashback. Because the antimicrobial coating can be minimally transparent, the coating can be applied to the outer surface in a striped pattern or other pattern that leaves a portion of the outer surface uncoated or minimally coated.
Abstract: The invention relates to an antimicrobial barrier device and methods of manufacture. The antimicrobial barrier comprises one or more antimicrobial drugs that inhibit biofilm formation and bacterial and/or fungal growth. The antimicrobial barrier is suited for use with insertable devices (e.g., catheters) to reduce the incidence of infection at and around the insertion site.
Abstract: A composition of stabilized chlorine dioxide at a concentration range of about 0.0004% to about 0.8% (w/v) having anti fungal properties to prevent oral fungal infections and method of use are disclosed.
Abstract: The present invention provides for a drug delivery device. The device can comprise at least one core with a first active pharmaceutical ingredient (API), coated with a first layer that is permeable or semi-permeable to the API, coated with a second layer that is impermeable to the API, and having a delivery window to allow passage of the API through the device and into body fluids or tissues. The device can also have a wicking material to modify the rate of transport of the API into the body fluid or tissues.
Type:
Grant
Filed:
June 6, 2012
Date of Patent:
April 10, 2018
Assignee:
OAK CREST INSTITUTE OF SCIENCE
Inventors:
John A. Moss, Thomas J. Smith, Marc M. Baum
Abstract: A coated balloon device for stabilizing a section of a blood vessel in a living subject is disclosed. The coating layer of the coated balloon comprises a phenolic compound having a plurality of phenolic groups connected to form a hydrophobic core with peripheral phenolic hydroxyl groups. The coating layer of the coated balloon may contain a hydrophilic polymer to facilitate the release of the phenolic compound. The balloon in general is made of a compliant polymer for atraumatic contact with the blood vessel. In some embodiments, the coating of the coated balloon device further comprises a hydrophilic undercoat layer between the balloon and the coating layer. In some embodiments, the coated balloon device further comprises a sacrificial top coating that dissolves upon delivery into the section of the blood vessel and comprises a hydrophilic composition including sugar, sugar derivatives, or a combination thereof.
Type:
Grant
Filed:
May 17, 2012
Date of Patent:
April 10, 2018
Assignee:
NECTERO MEDICAL, INC.
Inventors:
Matthew F. Ogle, Wenda C. Carlyle, Edward J. Anderson, Kishore Udipi
Abstract: Implantable materials for use with end effectors like surgical stapling devices, and methods associated with the operation of such end effectors, are provided herein. In one exemplary embodiment, a staple cartridge assembly includes a cartridge body and a hybrid adjunct material. The cartridge body has a plurality of staple cavities configured to seat staples therein. The hybrid adjunct material is releasably retained on the cartridge body and configured to be delivered to tissue by deployment of the staples in the cartridge body. The material includes a biologic tissue membrane, a synthetic substrate layer, and at least one compressible elastic member configured to compress when a compressive force is applied thereto, and to provide a spring back force when the compressive force is removed. Other implants, devices, and methods for surgical stapling are also provided.
Type:
Grant
Filed:
November 8, 2013
Date of Patent:
April 10, 2018
Assignee:
Ethicon LLC
Inventors:
Frederick E. Shelton, IV, Tamara S. Widenhouse
Abstract: The objective of the present invention is to provide a porous ultra-thin polymer film, and a method for producing said porous ultra-thin polymer film. The present invention provides a porous ultra-thin polymer film with a film thickness of 10 nm-1000 nm. In addition, the present invention provides a method for producing a porous ultra-thin polymer film, comprising the steps of: dissolving two types of mutually-immiscible polymers in a first solvent in an arbitrary proportion to obtain a solution; applying the solution onto a substrate and then removing the first solvent from the solution applied onto the substrate to obtain a phase-separated ultra-thin polymer film that has been phase-separated into a sea-island structure; and immersing the ultra-thin polymer film in a second solvent which is a good solvent for the polymer of the island parts but a poor solvent for a polymer other than the island parts to remove the island parts, thereby obtaining a porous ultra-thin polymer film.
Type:
Grant
Filed:
March 12, 2013
Date of Patent:
April 10, 2018
Assignees:
Nanotheta Co, Ltd., Toray Industries, Inc.
Inventors:
Shinji Takeoka, Akihiro Saito, Hong Zhang, Natsuki Takamizawa
Abstract: This invention relates to oral veterinary compositions for combating ectoparasites and endoparasites in animals, comprising at least one systemically-acting active agent in combination with a pharmaceutically acceptable carrier. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.
Type:
Grant
Filed:
December 22, 2015
Date of Patent:
April 3, 2018
Assignee:
MERIAL INC.
Inventors:
Mark David Soll, Diane Larsen, Susan Mancini Cady, Peter Cheifetz, Izabela Galeska, Saijun Gong
Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
Type:
Grant
Filed:
November 21, 2016
Date of Patent:
March 27, 2018
Assignees:
OPKO RENAL, LLC, OPKO IRELAND GLOBAL HOLDINGS, LIMITED
Inventors:
Charles W. Bishop, Samir P. Tabash, Sammy A. Agudoawu, Jay A. White, Eric J. Messner, P. Martin Petkovich, Keith H. Crawford
Abstract: Modular IOL systems including a base and a lens, wherein the lens includes fixed and actuatable tabs for connection to the base. The modular IOL allows for the lens to be adjusted or exchanged while leaving the base in place, either intra-operatively or post-operatively. Drug delivery capabilities and/or sensing capabilities may be incorporated into the base. Injector devices may be used to facilitate placement of the base and the lens sequentially or simultaneously into the eye.
Type:
Grant
Filed:
July 25, 2016
Date of Patent:
March 27, 2018
Assignees:
ClarVista Medical, Inc., The Regents of the University of Colorado, a body corporate
Inventors:
Malik Y. Kahook, Glenn Sussman, Paul McLean, Andrew Schieber
Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
Type:
Grant
Filed:
June 16, 2014
Date of Patent:
March 20, 2018
Assignees:
OPKO IRELAND GLOBAL HOLDINGS, LTD.
Inventors:
Charles W. Bishop, Samir P. Tabash, Sammy A. Agudoawu, Jay A. White, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich
Abstract: A bone material for hydration with a liquid is provided, the bone material comprising a coherent mass of milled and demineralized bone fibers, the coherent mass having no binder disposed in or on the coherent mass. In some embodiments, a bone material for hydration with a liquid is provided, the bone material comprising a coherent mass of cartridge milled, lyophilized and demineralized bone fibers, the coherent mass having no binder on the coherent mass. In some embodiments, a method of implanting a bone material is provided, the method comprising contacting the bone material with a liquid, the bone material comprising a coherent mass of cartridge milled, lyophilized and demineralized bone fibers, the coherent mass having no binder disposed in or on the coherent mass; molding the bone material into a shape to implant the bone material; and implanting the bone material at the target tissue site.
Type:
Grant
Filed:
November 13, 2015
Date of Patent:
March 13, 2018
Assignee:
Warsaw Orthopedic, Inc.
Inventors:
Kelly W. Schlachter, Daniel A. Shimko, Kerem N. Kalpakci, Erick Vasquez, David R. Kaes, Subhabrata Bhattacharyya
Abstract: The present invention relates to coated particles and pharmaceutical dosage forms comprising the active substances sensitive to environmental influences. The coating of the present invention provides stability and protection of the active substance to environmental influences and in particular from oxidation and/or environmental humidity by coating.
Type:
Grant
Filed:
September 10, 2015
Date of Patent:
March 6, 2018
Assignee:
Lek Pharmaceuticals d.d.
Inventors:
Vlasta Humar, Mateja Burjak, Rok Grahek, Mateja Salobir, Janez Kerc, Klemen Kocevar
Abstract: A composition for chemoembolotherapy of solid tumors comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.
Type:
Grant
Filed:
December 8, 2015
Date of Patent:
February 27, 2018
Assignee:
BIOCOMPATIBLES UK LIMITED
Inventors:
Andrew Lennard Lewis, Peter William Stratford, Simon Leppard, Pedro Garcia, Brenda Hall, Maria Victoria Fajardo Gonzalez
Abstract: The present invention generally relates to solid forms of tyrosine kinase inhibitors, in particular combinations of tyrosine kinase inhibitors with anti-oxidative acids, processes for its preparation and a pharmaceutical compositions containing the same.
Abstract: Differentiation and stability of neural stem cells can be enhanced by in vitro or in vivo culturing with one or more extracellular matrix (ECM) compositions, such as collagen I, IV, laminin and/or a heparan sulfate proteoglycan. In one aspect of the invention, adult mammalian enteric neuronal progenitor cells can be induced to differentiate on various substrates derived from components or combinations of neural ECM compositions. Collagen I and IV supported neuronal differentiation and extensive glial differentiation individually and in combination. Addition of laminin or heparan sulfate to collagen substrates unexpectedly improved neuronal differentiation, increasing neuron number, branching of neuronal processes, and initiation of neuronal network formation. In another aspect, neuronal subtype differentiation was affected by varying ECM compositions in hydrogels overlaid on intestinal smooth muscle sheets.